<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>cph8kex991020107.txt
<DESCRIPTION>PRESS RELEASE DATED FEBRUARY 6, 2007
<TEXT>

                                                                    Exhibit 99.1

Contact:

Crocker Coulson                               Donald Xu
President                                     Vice President, Strategic Planning
CCG Elite                                     China Pharma Holdings, Inc.
310 231-8600 ext 103                          858-776-8880
crocker.coulson@ccgir.com                     dxu@chinapharmaholdings.com
-------------------------                     ---------------------------


          China Pharma Announces Successful Private Placement of $3.85
                                    Million

HAIKOU CITY,  Hainan  Province,  PRC - February 6, 2007 - China Pharma Holdings,
Inc.   ("China   Pharma"  or  "the   Company")   (OTC  BB:  CPHI),  a  specialty
bio-pharmaceutical  company that develops,  manufactures and markets Western and
Chinese  medicines,  today  announced  that it has  successfully  completed  the
private  placement of  approximately  2.5 million shares of the Company's common
stock at the price of $1.70 per share and 2.5 million Class A 3-year warrants to
purchase an aggregate of 1.25 million shares of the Company's  common stock at a
strike price of $2.38 per share.  Net  proceeds to the Company of  approximately
$3.85 million will be used for  development of new drugs in pipeline and working
capital to support the Company's  growth.  Sterne,  Agee & Leach, Inc. served as
the sole placement agent for the offering.

"This financing  allows us to further the development of our new drugs at clinic
trial stage and provides the Company with additional  working capital to support
the launch of several  new drugs we have  recently  introduced  into the market.
This transaction benefits both our customers and shareholders, by expediting our
progress  of new drug  development  programs  and  strengthening  our  financial
position," commented Zhi-lin Li, China Pharma's President and CEO.

For more  detailed  information  on the  financing  referred to in this release,
reference  is made to the  Company's  Form 8-K filing  with the  Securities  and
Exchange Commission and related Exhibits thereto.

Neither the common stock nor the warrants  referred to in this release have been
registered under the Securities Act of 1933 and may not be subsequently  offered
or sold by investors in the United States absent  registration  or an applicable
exemption from the  registration  requirement.  The Company has agreed to file a
registration  statement  covering resale of the common stock and the warrants by
investors.  This  press  release  does  not  constitute  an offer to sell or the
solicitation  of an offer to buy any security and shall not constitute an offer,
solicitation or sale of any securities in any  jurisdiction in which such offer,
solicitation or sale would be unlawful prior to  registration  or  qualification
under the securities laws of such jurisdiction.

<PAGE>

About China Pharma Holdings, Inc.

China Pharma  Holdings,  Inc.  develops,  manufactures,  and markets generic and
brand  bio-pharmaceutical   products  in  China  that  treat  a  wide  range  of
conditions,  including infections,  hepatitis,  vascular diseases, CNS and other
prevailing diseases.  Helpson Bio-pharmaceutical Co., Ltd (Helpson), a specialty
bio-pharmaceutical  company  headquartered  in Haikou City,  Hainan  province in
China,  is a  wholly  owned  subsidiary  of  China  Pharma  Holdings.  For  more
information, visit the company's website at www.chinapharmaholdings.com.

Safe Harbor  Statement  Under the Private  Securities  Litigation  Reform Act of
1995:  Any  statements  set  forth  above  that  are not  historical  facts  are
forward-looking statements that involve risks and uncertainties that could cause
actual  results  to  differ   materially  from  those  in  the   forward-looking
statements,  which  may  include,  but are  not  limited  to,  such  factors  as
unanticipated  changes  in product  demand,  increased  competition,  failure to
obtain or maintain  intellectual  property protection,  downturns in the Chinese
economy,  uncompetitive  levels of research and  development,  failure to obtain
regulatory  approvals,  and other information  detailed from time to time in the
Company's  filings and future  filings  with the United  States  Securities  and
Exchange Commission.

                                      # # #
</TEXT>
</DOCUMENT>
